Cantor raises target to USD 145 for Merck stock

Published on 10/09/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor raised its target from USD 120.00 to USD 145.00 on October 8, 2026. Merck stock costs EUR 127.08 versus EUR 126.52, plus 0.44 percent.

Key points in brief

Cantor Fitzgerald raised its Merck target from USD 120.00 to USD 145.00 on October 8, 2026.
Merck stock was trading at EUR 127.08 at Lang & Schwarz on October 9, 2026, plus 0.44 percent versus EUR 126.52.
Second-quarter 2026 revenue reached USD 16.61 billion, up 5.10 percent year over year.
The next scheduled earnings call is October 29, 2026, ahead of upcoming oncology data presentations.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was trading at EUR 127.08 at Lang & Schwarz on October 9, 2026 at 2:51 p.m. CEST, up 0.44 percent versus the prior close of EUR 126.52. On October 8, 2026, Cantor Fitzgerald raised its Merck price target from USD 120.00 to USD 145.00 while keeping a Neutral rating, according to Investing.com.

Three dated company milestones

On August 4, 2026, Merck reported second-quarter revenue of USD 16.61 billion, up 5.10 percent year over year, according to MarketBeat. On September 30, 2026, Merck reported that high-dose tulisokibart produced a 72 percent HiSCR50 response rate in a Phase 2b study, versus 35 percent for placebo, according to Business Wire. On October 8, 2026, Cantor lifted its target to USD 145.00 from USD 120.00, according to Investing.com.

What does the target change mean?

Cantor's USD 145.00 target is 1.83 percent above Merck's last USD quote of USD 142.40 on the NYSE at 3:59 p.m. ET on October 8, 2026. The target increase therefore leaves the analyst's valuation only modestly above the latest US-listed price, while the euro quote remains below that dollar reference because the currencies and venues differ.

Guggenheim kept a Buy rating and a USD 170.00 target on October 8, 2026, but cut its third-quarter 2026 sales estimate from USD 17.52 billion to USD 17.44 billion and its earnings-per-share estimate from USD 2.24 to USD 2.08, according to Investing.com.

Upcoming dates and data

The next dated events are October 23-27, 2026, when oncology data are scheduled for presentation at the ESMO Congress, and October 29, 2026, when Merck will hold its third-quarter sales and earnings conference call. Merck confirmed the October 29 call in a release dated October 1, 2026, published on Merck.

For the October 9, 2026 session, the Lang & Schwarz quote stood at EUR 127.08, plus 0.44 percent versus the EUR 126.52 prior close dated October 8, 2026. The continuously updated real-time quote of Merck & Co. stock.